Thioredoxin Systems AB – Trademark Portfolio
Entity Type: 03
Thioredoxin Systems AB holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 37 (Building & Construction) — 1 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 9 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include EBSARGENT.
RORGÄNGARGATAN 3 LGH 1302
SE-120 68 Stockholm
Showing of trademarks Trademarks
Trademark Classifications
Thioredoxin Systems AB's trademark portfolio spans 9 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Apparatus for lighting, heating, steam generating, cooking, refrigerating, drying
Paints, varnishes, lacquers; preservatives against rust and against deterioration of wood
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Frequently Asked Questions
How many trademarks does Thioredoxin Systems AB have?
Thioredoxin Systems AB has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does Thioredoxin Systems AB file in?
Thioredoxin Systems AB files trademarks across 9 Nice Classification classes. The most active classes are Class 37 (Building & Construction), Class 1 (Chemicals), Class 11 (Environmental Control), Class 24 (Fabrics), Class 20 (Furniture). Class 37 covers building construction; repair; installation services.
What are Thioredoxin Systems AB's most well-known trademarks?
Thioredoxin Systems AB's registered trademark portfolio includes well-known marks such as EBSARGENT. These are among 1 currently registered trademark in the portfolio.
What is Thioredoxin Systems AB's trademark registration success rate?
Thioredoxin Systems AB has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.